111 Capital Buys 2,116 Shares of Intuitive Surgical, Inc. $ISRG

111 Capital raised its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 59.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,658 shares of the medical equipment provider’s stock after acquiring an additional 2,116 shares during the quarter. Intuitive Surgical makes up about 0.7% of 111 Capital’s portfolio, making the stock its 24th biggest position. 111 Capital’s holdings in Intuitive Surgical were worth $3,204,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of ISRG. Brighton Jones LLC boosted its position in Intuitive Surgical by 24.9% during the 4th quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider’s stock valued at $1,916,000 after acquiring an additional 731 shares in the last quarter. Sivia Capital Partners LLC boosted its position in Intuitive Surgical by 3.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 928 shares of the medical equipment provider’s stock valued at $504,000 after acquiring an additional 34 shares in the last quarter. Schnieders Capital Management LLC. boosted its position in Intuitive Surgical by 38.0% during the 2nd quarter. Schnieders Capital Management LLC. now owns 973 shares of the medical equipment provider’s stock valued at $529,000 after acquiring an additional 268 shares in the last quarter. Osterweis Capital Management Inc. bought a new stake in Intuitive Surgical during the 2nd quarter valued at $200,000. Finally, Main Street Financial Solutions LLC boosted its position in Intuitive Surgical by 92.4% during the 2nd quarter. Main Street Financial Solutions LLC now owns 2,929 shares of the medical equipment provider’s stock valued at $1,592,000 after acquiring an additional 1,407 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on ISRG shares. Barclays set a $651.00 target price on Intuitive Surgical and gave the company an “overweight” rating in a research report on Thursday, April 23rd. HSBC decreased their price objective on Intuitive Surgical from $653.00 to $604.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. UBS Group decreased their price objective on Intuitive Surgical from $570.00 to $550.00 and set a “neutral” rating for the company in a report on Tuesday, March 17th. Leerink Partners decreased their price objective on Intuitive Surgical from $622.00 to $573.00 and set an “outperform” rating for the company in a report on Wednesday, April 22nd. Finally, BTIG Research reiterated a “buy” rating and set a $574.00 price objective on shares of Intuitive Surgical in a report on Wednesday, April 22nd. Nineteen equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $573.63.

Intuitive Surgical Trading Up 0.8%

Shares of ISRG opened at $422.06 on Friday. Intuitive Surgical, Inc. has a 12 month low of $396.68 and a 12 month high of $603.88. The stock has a fifty day moving average price of $447.24 and a 200-day moving average price of $501.02. The firm has a market cap of $149.48 billion, a PE ratio of 51.16, a P/E/G ratio of 3.34 and a beta of 1.46.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Tuesday, April 21st. The medical equipment provider reported $2.50 EPS for the quarter, beating the consensus estimate of $2.08 by $0.42. Intuitive Surgical had a return on equity of 15.98% and a net margin of 28.15%.The firm had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.62 billion. During the same quarter in the prior year, the business posted $1.81 EPS. The business’s revenue for the quarter was up 23.0% compared to the same quarter last year. As a group, research analysts forecast that Intuitive Surgical, Inc. will post 8.57 EPS for the current year.

Insider Buying and Selling

In related news, EVP Gary Loeb sold 400 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $446.95, for a total value of $178,780.00. Following the completion of the transaction, the executive vice president owned 6,120 shares in the company, valued at $2,735,334. This trade represents a 6.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Mark Brosius sold 645 shares of the firm’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $485.01, for a total value of $312,831.45. Following the completion of the transaction, the senior vice president owned 1,613 shares of the company’s stock, valued at $782,321.13. This trade represents a 28.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 7,448 shares of company stock worth $3,224,404 over the last three months. Corporate insiders own 0.60% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.